Company profile: Biotest
1.1 - Company Overview
Company description
- Provider of plasma proteins and biotherapeutic drugs for haematology, clinical immunology and intensive care medicine, developing, manufacturing and marketing immunoglobulins and clotting factors, with a value chain extending from pre-clinical and clinical development to worldwide marketing and distribution.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Biotest
Retrophin
HQ: United States
Website
- Description: Provider of therapies and programs for rare diseases, including FILSPARI (sparsentan) for adults with IgA nephropathy; a late-stage therapy for focal segmental glomerulosclerosis; a potential disease-modifying therapy for classical homocystinuria; preclinical Alagille syndrome research with NIH and ALGSA; and support for newborn screening modernization and a telehealth model to improve specialist access.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Retrophin company profile →
Barentz
HQ: The Netherlands
Website
- Description: Provider of specialty ingredients for pharmaceutical, personal and home care, food & nutrition, and animal nutrition markets worldwide, representing world-class suppliers and Barentz-owned producers. Includes APIs, excipients, nutraceuticals, functional actives, intermediates, alternative proteins, clean label, sugar/sodium reduction, fortification, and animal nutrition concepts, plus technical/formulation support and supply chain, warehousing and transport solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Barentz company profile →
Trevi Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for uremic pruritus and chronic cough, including Haduvio—an investigational oral nalbuphine ER therapy targeting the central and peripheral nervous systems for idiopathic pulmonary fibrosis (IPF)-related cough and refractory chronic cough (RCC).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trevi Therapeutics company profile →
KAI Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel therapeutics through drug discovery and development, with multiple clinical-stage programs in cardiovascular disease, kidney disease, and pain; lead candidate KAI-9803 is in Phase 2b (PROTECTION AMI) evaluating reduction of myocardial injury in heart attack.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KAI Pharmaceuticals company profile →
Herborium
HQ: United States
Website
- Description: Provider of botanical therapeutics that develops, licenses, and markets proprietary botanical-based medicinal products. Offerings include AcnEase, a herbal acne and rosacea treatment; the Virtual Institute for Natural and Complementary Medicine, an educational platform for integrative medicine; the Kamasutra Spirits product line; and Herborium Botanical Therapeutics addressing dermatological needs and sexual disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Herborium company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Biotest
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Biotest
2.2 - Growth funds investing in similar companies to Biotest
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Biotest
4.2 - Public trading comparable groups for Biotest
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →